| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.VACCINE.2009.07.038 |
| P698 | PubMed publication ID | 19651171 |
| P50 | author | Joanne M. Langley | Q42178451 |
| Allison McGeer | Q42226756 | ||
| P2093 | author name string | Elaine Wang | |
| Minran Li | |||
| Gerald Predy | |||
| William Meekison | |||
| Jose Capellan | |||
| Roland Guasparini | |||
| Valerie Sales | |||
| P2860 | cites work | Respiratory syncytial virus infection in adults | Q33961877 |
| Respiratory syncytial virus infection in elderly and high-risk adults | Q34414401 | ||
| Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective, population based study of disease burden | Q36246809 | ||
| Respiratory syncytial virus infection in the elderly | Q40662545 | ||
| An epidemic of respiratory syncytial virus in elderly people: clinical and serological findings | Q40765474 | ||
| Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines--nonadjuvanted vaccine or vaccine adjuvanted with alum--given concomitantly with influenza vaccine to high-risk elderly individuals | Q44480572 | ||
| Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults | Q44982507 | ||
| Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults | Q45623141 | ||
| Risk factors for severe respiratory syncytial virus infection in elderly persons | Q45699277 | ||
| Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly | Q45760956 | ||
| Severity of respiratory syncytial virus infection is related to virus strain | Q45764062 | ||
| Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. | Q45765792 | ||
| Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults | Q45768811 | ||
| Immunity to and frequency of reinfection with respiratory syncytial virus | Q45853042 | ||
| P433 | issue | 42 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vaccine | Q134808 |
| aluminium | Q663 | ||
| P304 | page(s) | 5913-5919 | |
| P577 | publication date | 2009-08-03 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age. | |
| P478 | volume | 27 |
| Q34884984 | A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice |
| Q27312129 | A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models |
| Q38130514 | Advances in and the potential of vaccines for respiratory syncytial virus |
| Q36500189 | An adjuvanted respiratory syncytial virus fusion protein induces protection in aged BALB/c mice |
| Q34504791 | Biological challenges and technological opportunities for respiratory syncytial virus vaccine development |
| Q45359726 | Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice |
| Q37153656 | Contamination of DNase Preparations Confounds Analysis of the Role of DNA in Alum-Adjuvanted Vaccines |
| Q34396689 | Current concepts and progress in RSV vaccine development. |
| Q37634138 | Immunostimulant patches containing Escherichia coli LT enhance immune responses to DNA- and recombinant protein-based Alzheimer's disease vaccines. |
| Q90681995 | Impact of Respiratory Syncytial Virus Infection on the Host Cell: Implications for Antiviral Strategies |
| Q34033869 | Intranasal immunization with W 80 5EC adjuvanted recombinant RSV rF-ptn enhances clearance of respiratory syncytial virus in a mouse model |
| Q37242530 | Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV. |
| Q35914345 | Nonglycosylated G-Protein Vaccine Protects against Homologous and Heterologous Respiratory Syncytial Virus (RSV) Challenge, while Glycosylated G Enhances RSV Lung Pathology and Cytokine Levels |
| Q36005960 | Novel antigens for RSV vaccines |
| Q56894869 | Progress in respiratory virus vaccine development |
| Q37991125 | Prophylaxis and treatment of respiratory syncytial virus in adult immunocompromised patients |
| Q38617302 | Recent advances in the development of subunit-based RSV vaccines. |
| Q56893551 | Respiratory syncytial virus vaccine development |
| Q38803541 | Respiratory syncytial virus vaccines: an update on those in the immediate pipeline. |
| Q57988219 | Structural vaccinology starts to deliver |
| Q37328584 | Targeting RSV with vaccines and small molecule drugs |
| Q38630273 | The epidemiology of medically attended respiratory syncytial virus in older adults in the United States: A systematic review |
| Q40933366 | The preventive effect of vaccine prophylaxis on severe respiratory syncytial virus infection: A meta-analysis. |
| Q33596091 | The source of respiratory syncytial virus infection in infants: a household cohort study in rural Kenya |
| Q37514757 | Vaccination against RSV: is maternal vaccination a good alternative to other approaches? |
| Q38868960 | Vaccination against respiratory syncytial virus in pregnancy: a suitable tool to combat global infant morbidity and mortality? |
| Q45326393 | Vaccine Prevention of Respiratory Syncytial Virus in Older Adults: The Work Continues |
| Q39318444 | Vaccine development for respiratory syncytial virus |
| Q24201977 | Vaccines for the common cold |
| Q38682527 | Vaccines for the common cold |
| Q28729792 | What Are the Most Powerful Immunogen Design Vaccine Strategies? |
| Q64098587 | Will Attention by Vaccine Developers to the Host's Nuclear Hormone Levels and Immunocompetence Improve Vaccine Success? |
Search more.